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Drug resistance exerts a crucial role in several 
cancer treatments. Understanding the resistance 
mechanisms against different therapeutic agents 
can be helpful to determine the prognosis, but 
remains a tricky task. In this context, tumor-
derived exosomes (TDEs) may give crucial 
answers about these resistance mechanisms. 
Exosomes are biological nanovesicles with an 
average size around 30–100 nm of diameter 
(Figure 1) that originate from the endocytic path-
way by the inward budding of multivesicular bod-
ies (MVB), and they function as cell-free 
messengers, involved in the cell–cell communica-
tion [Kowal et al. 2014]. It has been demonstrated 
that both cells in physiological and pathological 
conditions release exosomes and that exosomes 
are easily detected in several body fluids, such as 
plasma, serum, urine, saliva, etc. [Rolfo et  al. 
2014]. It has been demonstrated that TDEs con-
tain different proteins, lipids, mRNAs and miR-
NAs and have pleiotropic functions in the tumor 
microenvironment, tumor growth and progres-
sion, immune escape, angiogenesis, invasion, and 
drug resistance [Kowal et  al. 2014; Rolfo et  al. 
2014; Fontana et al. 2013].
Currently, there are three frequently described 
exosome-mediated drug resistance mechanisms: 
drug export via the exosome pathway, neutraliza-
tion of antibody-based drugs and exosome-
mediated transfer of miRNAs (Figure 2) [Chen 
et al. 2014b; Ciravolo et al. 2012; Corcoran et al. 
2012; Safaei et al. 2005; Wei et al. 2014].
In a preclinical study, it was demonstrated that 
exosomes released from cisplatin-resistant ovar-
ian carcinoma cells contained 2.6-fold more cis-
platin respect to exosomes released from 
cisplatin-sensitive ovarian carcinoma cells, sug-
gesting that cancer cells exploited the endocytic 
compartment as drug export vector [Safaei et al. 
2005]. In addition, it was also described that can-
cer cells can release drugs or their metabolites 
through exosomal pathway mediated by ABC 
transport. In this context, it was demonstrated in 
prostate cancer that exosomal transfer of multid-
rug resistance proteins such as multidrug resist-
ance protein 1 (MDR-1/P-gp) could be related to 
docetaxel resistance [Corcoran et  al. 2012]. 
Interestingly, an exosome-mediated transfer of 
MDR-1 from nonsensitive to sensitive breast can-
cer cells to docetaxel was observed, transferring 
docetaxel drug resistance to sensitive cells [Lv 
et al. 2014]. It was also described that mesenchy-
mal stem cells derived exosomes could induce, 
both in vivo and ex vivo, 5-fluorouracil drug 
resistance in gastric cancer cells enhancing the 
expression of MDR-1, lung resistance protein 
(LRP) and multidrug resistance-related protein 
(MRP) through CaM-Ks/Raf/MEK/ERK path-
way activation [Ji et al. 2015].
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Figure 1. Image of exosomes, released in the plasma 
of a non-small cell lung cancer patient, performed 
through transmission electron microscopy analysis.
This experiment was performed with UZA Hospital (Edegem, 
Belgium) ethical committee approval.
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The idea to discover the mechanisms that lead to 
early antibody-based drug resistance in cancer 
cells is very attractive. In this field, Ciravolo and 
colleagues described that, both in vitro and in 
vivo, TDEs are involved into neutralizing anti-
body-based drugs: HER2-overexpressing breast 
carcinoma cell lines released TDEs containing 
HER2 protein that could bind the anti-HER2 
antibody trastuzumab. This interaction leads to a 
decrease in the real amount of antibody-based 
drug that can interact with cancer cells and even-
tually decreased the overall effect of trastuzumab 
[Ciravolo et al. 2012].
During the last few years, there is a lot of interest 
in drug resistance by exosome-mediated transfer 
of miRNAs. Currently, several studies indicate 
that TDEs function also as a genetic exchange 
vector in the tumor microenviroment. Several in 
vitro studies suggest that breast cancer cells resist-
ant to different drugs (docetaxel–adriamycin–
tamoxifen) may transfer the resistance to sensitive 
cells in part by exosomal miRNAs exchange 
[Chen et  al. 2014a, 2014b; Wei et  al. 2014]. 
Similar results were obtained in ovarian cancer 
preclinical studies, it was demonstrated that a 
cisplatin-resistant ovarian cancer cell line trans-
fers the resistance to sensitive cells by exosomal 
exchange of biologically active miR-21-3p, which 
targeted the NAV3 gene [Pink et  al. 2015]. 
Moreover, the role of exosomal miRNAs in drug 
resistance mediated by the cross-talk with the 
tumor microenviroment in neuroblastoma 
(NBL) was investigated. In a preclinical study, 
Challagundla and colleagues demonstrated that 
exosomes released from the NBL cell line trans-
ferred the oncomiR-21 to human monocytes. 
This genetic information exchange led monocytes 
to transcribe oncomiR-155 in a NF-κB-dependent 
pathway and, interestingly, monocytes released 
exosomes containing miR-155 that was, in turn, 
internalized by NBL cells. One of described tar-
get of miR-155 is TERF1, a telomerase inhibitor; 
silencing of TERF1 mRNAs caused alterations of 
telomerase activity, which could lead to an 
increased resistance to DNA-damage induced by 
cisplatin [Challagundla et al. 2015]. Furthermore, 
other exosomal proteins lead to a drug-resistant 
phenotype changes in the target cells, for exam-
ple, it has been demonstrated that PTEN is 
released in exosomes thus exerting biological 
functions in target cells [Putz et  al. 2012]. 
Moreover, it has been described that the loss of 
function of PTEN increases resistance to chemo-
therapeutic and sensitivity to mTOR inhibitors in 
breast cancer and, then, PTEN exosomal transfer 
could be exploited as a transfer mechanism of 
drug resistance changes [Steelman et al. 2008].
Altogether, these findings suggest a crucial role for 
exosomes in drug resistance in several tumor types. 
Notable, in the liquid biopsy research field, it could 
be an attractive idea to analyze selected exosome 
groups among the total population in different 
Figure 2. Overview of three well-described exosome-mediated drug-resistance mechanisms.
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body fluids. Regrettably, especially in cancer 
patients, the challenge for a good discrimination of 
TDEs among the total exosome population in 
body fluids (such as in blood) is still open. 
However, it seems that the amount of TDEs is 
prevalent in the total exosome population [Milane 
et al. 2015]. The new era of liquid biopsies is grow-
ing very fast, and less-known components, such as 
exosomes, may also be exploited as a source of bio-
markers. Could exosomal drug resistance bio-
markers finally be used in clinical practice? 
Probably the near future is here, and after more 
research and validation, exosomal drug resistance 
biomarkers could lead to a more defined insight 
into resistance mechanisms against several tar-
geted therapies in cancer.
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